SCHEMBL5456835

SCHEMBL5456835

COc1ccc(N2CCN(C)CC2)c2c1CCN(C(=O)Cc1ccc(NCc3ccccc3)cc1)C2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.49
KMT2A Q03164 1/20 0.49
HTR1A P08908 6/20 0.46
HTR1D P28221 6/20 0.46
HTR1B P28222 6/20 0.46
TMEM97 Q5BJF2 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
PTGDR2 Q9Y5Y4 5/20 0.44
GAA P10253 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTR6 P50406 2/20 0.44
NAMPT P43490 1/20 0.42
ALOX15 P16050 1/20 0.42
ALOX12 P18054 1/20 0.42
MAPK1 P28482 1/20 0.42
GFER P55789 1/20 0.42
HTR2A P28223 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456931 0.93 MAPT (0.50) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5453639 0.92 NPC1 (0.48) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5450240 0.92 KDM4E (0.45) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5452185 0.91 HTR1A (0.46) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5445015 0.91 NPC1 (0.58) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5454903 0.90 NPC1 (0.53) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5455131 0.89 NPC1 (0.45) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5446338 0.87 KMT2A (0.52) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5445301 0.87 ABCB1 (0.49) NPC1KMT2AHTR1AHTR1DHTR1B
SCHEMBL5465837 0.87 USP2 (0.49) NPC1KMT2ATMEM97SIGMAR1PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed
US-20070010526-A1 Therapeutic isoquinoline compounds ASTRAZENECA AB (SE) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010526-A1 Therapeutic isoquinoline compounds HTR1B, HTR1D, HTR1A NPC1 1664/4885KMT2A 1271/4885HTR1A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.